Massachusetts Financial Services Co. MA Makes New $25.96 Million Investment in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Massachusetts Financial Services Co. MA acquired a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 236,488 shares of the medical equipment provider's stock, valued at approximately $25,955,000. Massachusetts Financial Services Co. MA owned 0.34% of Lantheus as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also made changes to their positions in the company. Signaturefd LLC increased its holdings in shares of Lantheus by 40.5% in the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider's stock valued at $35,000 after purchasing an additional 92 shares during the period. Silverberg Bernstein Capital Management LLC lifted its stake in shares of Lantheus by 0.4% in the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 22,843 shares of the medical equipment provider's stock worth $1,834,000 after acquiring an additional 100 shares during the period. UMB Bank n.a. boosted its holdings in shares of Lantheus by 42.1% in the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider's stock valued at $47,000 after acquiring an additional 126 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Lantheus by 45.5% during the third quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider's stock worth $51,000 after acquiring an additional 146 shares during the period. Finally, Moody National Bank Trust Division raised its holdings in Lantheus by 1.1% during the second quarter. Moody National Bank Trust Division now owns 14,984 shares of the medical equipment provider's stock worth $1,203,000 after purchasing an additional 162 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.

Lantheus Stock Performance

NASDAQ LNTH traded down $1.43 during trading hours on Tuesday, reaching $89.53. The company's stock had a trading volume of 1,246,380 shares, compared to its average volume of 1,023,089. The company's 50-day moving average is $102.80 and its two-hundred day moving average is $97.04. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $126.89. The stock has a market cap of $6.22 billion, a PE ratio of 14.94 and a beta of 0.51.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on LNTH. Truist Financial reaffirmed a "buy" rating and issued a $120.00 price objective (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. JMP Securities decreased their price target on Lantheus from $125.00 to $112.00 and set a "market outperform" rating on the stock in a research note on Thursday, November 7th. Redburn Atlantic began coverage on Lantheus in a research report on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 price objective for the company. Finally, StockNews.com cut shares of Lantheus from a "buy" rating to a "hold" rating in a research note on Thursday, November 21st. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $122.50.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.